The headline reads as positive (76% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The rest of the picture is mixed, so the headline alone is not enough for a clear call.
Stocks › LQDA
Liquidia Corporation (LQDA) stock analysis
SKIP 3% confidence · analysed Oct 14, 2026
On Oct 14, 2026, our model rated Liquidia Corporation (LQDA) SKIP with 3% confidence at a price of $26.81. That means the signals cancel out; the model sees no clear edge either way.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Market cap2.40B
Analysed price$26.81
Technical picture
The 14-day RSI is 18, below 30, which is oversold territory: sellers have pushed hard recently. Oversold stocks often bounce, but they can stay weak for a while.
MACD is below its signal line, so short-term momentum is pointing down.
The price is below both its 50-day and 200-day moving averages, the classic picture of a downtrend.
Volume is about normal (0.8x the 20-day average).
Trend structure and money flow
Market structure shows a bearish break of structure (BOS): price broke a recent swing low in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $46.67 and the swing low is $29.12; traders often treat these as resistance and support.
Fundamentals
The company reports a profit margin of 30.7% and revenue growth of +1842.7%.
In its latest quarter it earned $0.74 per share, which missed the $0.85 analysts expected, with revenue +1842.7% year over year.
Wall Street's average rating is 2.2 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $49.33.
The next earnings report is expected around Nov 3, 2026; prices often move sharply around earnings.
The model's one-paragraph read
No clear edge (SKIP) — composite score -0.03 (SKIP). Technicals: RSI 18.31, MACD bearish, price below SMA50. Fundamentals: margin 30.7%, revenue growth 1842.7%. Financial results: YoY revenue +1842.7%, last EPS surprise -12.9%, next earnings 2026-11-03. Smart Money Concepts: BOS bearish (trend continuation). FinGPT news read: neutral. Memory: 2 prior look(s). Reference price $33.81; no trade levels (SKIP).
Past ratings for LQDA
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 14, 2026 | SKIP | 3% | $26.81 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on LQDA
Oct 14, 2026 · Liquidia shares surge to 5-month high premarket on United Therapeutics settlement
Oct 14, 2026 · Liquidia stock surges 40% on $380.7M litigation settlement with UTHR
The headline reads as positive (2% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The rest of the picture is mixed, so the headline alone is not enough for a clear call.
Oct 13, 2026 · Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH
The headline reads as positive (94% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The rest of the picture is mixed, so the headline alone is not enough for a clear call.
- Oct 14, 2026: LQDA Stock Rockets 40% Today BTIG Calls United Therapeutics Settlement Better Than Best-Case Scenario (Stocktwits)
- Oct 14, 2026: ?? Under the Radar: Liquidia Stock Soars After Settling Patent Fight (The Wall Street Journal)
- Oct 14, 2026: Liquidia settles six lawsuits with United Therapeutics, securing uninterrupted Yutrepia access (Reuters)
- Oct 14, 2026: This Biotech Stock Surges 37% on Patent Settlement. 'Better Than the Best-Case Scenario.' (Barrons.com)
- Oct 14, 2026: Liquidia settled all six pending lawsuits with United Therapeutics, preserving uninterrupted access to Yutrepia (Reuters)
- Oct 14, 2026: Premarket movers: Alibaba gains on new AI glasses; Liquidia rallies as legal eases (Investing.com)
- Oct 14, 2026: Liquidia shares surge to 5-month high premarket on United Therapeutics settlement (Investing.com)
- Oct 13, 2026: LQDA Explodes After Hours On Deal Ending Years Of Patent Fight, Keeping YUTREPIA On Market (Stocktwits)
Other Healthcare stocks we cover
MDT · NRC · NVO · OSCR · PCRX · PFE · PGNY · PHR · PRGO · SDZNY · SLS · SNN
Frequently asked questions
Is LQDA a buy right now?
As of Oct 14, 2026, our automated model rates Liquidia Corporation (LQDA) SKIP with 3% confidence: the signals cancel out; the model sees no clear edge either way. This is a model output for education, not personal investment advice.
When does Liquidia Corporation report earnings next?
The next earnings report is expected around Nov 3, 2026.
What does a SKIP rating mean?
A SKIP rating means the signals cancel out; the model sees no clear edge either way.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.